Relapsed/refractory DLBCL patient characteristics
| . | . | P . | ||
|---|---|---|---|---|
| Entire group (n = 228) . | 2006-2010 (n = 103) . | 2011-2015 (n = 125) . | ||
| Age at auto-HCT, y | .96 | |||
| Median | 60 | 59 | 60 | |
| Range | 25-77 | 32-77 | 25-77 | |
| Sex | .85 | |||
| Male | 152 (67) | 68 (66) | 84 (67) | |
| Female | 76 (33) | 35 (34) | 41 (33) | |
| ECOG PS at auto-HCT | .22 | |||
| 0 | 36 (17) | 17 (18) | 19 (16) | |
| 1 | 173 (80) | 76 (82) | 97 (79) | |
| 2 | 6 (3) | 0 | 6 (5) | |
| Missing | 13 | 10 | 3 | |
| DLBCL subtype | .76 | |||
| GCB | 38/66 (58) | 7/13 (54) | 31/53 (58) | |
| Non-GCB | 28/66 (42) | 6/13 (46) | 22/53 (42) | |
| DHL/THL | 9/91 (10) | 3/19 (16) | 6/72 (8) | .39 |
| Time from diagnosis to auto-HCT, y | .36 | |||
| ≤1* | 46 (20) | 18 (17) | 28 (22) | |
| >1 | 184 (80) | 85 (83) | 97 (78) | |
| Time from diagnosis to auto- HCT, mo | .28 | |||
| Median | 20.1 | 21.4 | 18.6 | |
| Range | 3.9-268 | 5.2-253 | 3.9-268 | |
| Lines of therapy before auto-HCT | .71 | |||
| Median | 2.0 | 2.0 | 2.0 | |
| Range | 1.0-4.0 | 1.0-4.0 | 1.0-4.0 | |
| Remission status at auto-HCT | .80 | |||
| CR | 115 (50) | 51 (50) | 64 (51) | |
| Partial remission | 113 (50) | 52 (50) | 61 (49) | |
| PB graft type | 228 (100) | 103 (100) | 125 (100) | — |
| Conditioning regimen | .29 | |||
| BEAM | 210 (92) | 97 (94) | 113 (90) | |
| Other | 18 (8) | 6 (6) | 12 (10) | |
| Timing of relapse after auto-HCT, y | .53 | |||
| ≤1 | 151 (66) | 66 (64) | 85 (68.0) | |
| >1 | 77 (34) | 37 (36) | 40 (32.0) | |
| Time from auto-HCT to relapse, mo | .22 | |||
| Median | 6.2 | 6.4 | 6.1 | |
| Range | 0.8-96.6 | 0.9-96.6 | 0.8-60.2 | |
| Salvage therapy post auto-HCT relapse | ||||
| Lines of therapy | ||||
| Median | 1 | 1 | 1 | |
| Range | 0-9 | 0-6 | 0-9 | |
| Lenalidomide | 41/228 (18) | 15/103 (15) | 26/125 (21) | .22 |
| Ibrutinib | 15/228 (7) | 4/103 (4) | 11/125 (9) | .14 |
| Checkpoint inhibitors | 8/220 (4) | 1/103 (1) | 7/125 (6) | .08 |
| Allogeneic HCT | 48/228 (21) | 26/103 (25) | 22/125 (18) | .16 |
| Clinical trials† | 38/228 (17) | 15/103 (15) | 23/125 (19) | .44 |
| FU post–auto-HCT relapse, mo | ||||
| Median | 39 | 63 | 35 | |
| Range | 1-72 | 5-72 | 1-72 | |
| . | . | P . | ||
|---|---|---|---|---|
| Entire group (n = 228) . | 2006-2010 (n = 103) . | 2011-2015 (n = 125) . | ||
| Age at auto-HCT, y | .96 | |||
| Median | 60 | 59 | 60 | |
| Range | 25-77 | 32-77 | 25-77 | |
| Sex | .85 | |||
| Male | 152 (67) | 68 (66) | 84 (67) | |
| Female | 76 (33) | 35 (34) | 41 (33) | |
| ECOG PS at auto-HCT | .22 | |||
| 0 | 36 (17) | 17 (18) | 19 (16) | |
| 1 | 173 (80) | 76 (82) | 97 (79) | |
| 2 | 6 (3) | 0 | 6 (5) | |
| Missing | 13 | 10 | 3 | |
| DLBCL subtype | .76 | |||
| GCB | 38/66 (58) | 7/13 (54) | 31/53 (58) | |
| Non-GCB | 28/66 (42) | 6/13 (46) | 22/53 (42) | |
| DHL/THL | 9/91 (10) | 3/19 (16) | 6/72 (8) | .39 |
| Time from diagnosis to auto-HCT, y | .36 | |||
| ≤1* | 46 (20) | 18 (17) | 28 (22) | |
| >1 | 184 (80) | 85 (83) | 97 (78) | |
| Time from diagnosis to auto- HCT, mo | .28 | |||
| Median | 20.1 | 21.4 | 18.6 | |
| Range | 3.9-268 | 5.2-253 | 3.9-268 | |
| Lines of therapy before auto-HCT | .71 | |||
| Median | 2.0 | 2.0 | 2.0 | |
| Range | 1.0-4.0 | 1.0-4.0 | 1.0-4.0 | |
| Remission status at auto-HCT | .80 | |||
| CR | 115 (50) | 51 (50) | 64 (51) | |
| Partial remission | 113 (50) | 52 (50) | 61 (49) | |
| PB graft type | 228 (100) | 103 (100) | 125 (100) | — |
| Conditioning regimen | .29 | |||
| BEAM | 210 (92) | 97 (94) | 113 (90) | |
| Other | 18 (8) | 6 (6) | 12 (10) | |
| Timing of relapse after auto-HCT, y | .53 | |||
| ≤1 | 151 (66) | 66 (64) | 85 (68.0) | |
| >1 | 77 (34) | 37 (36) | 40 (32.0) | |
| Time from auto-HCT to relapse, mo | .22 | |||
| Median | 6.2 | 6.4 | 6.1 | |
| Range | 0.8-96.6 | 0.9-96.6 | 0.8-60.2 | |
| Salvage therapy post auto-HCT relapse | ||||
| Lines of therapy | ||||
| Median | 1 | 1 | 1 | |
| Range | 0-9 | 0-6 | 0-9 | |
| Lenalidomide | 41/228 (18) | 15/103 (15) | 26/125 (21) | .22 |
| Ibrutinib | 15/228 (7) | 4/103 (4) | 11/125 (9) | .14 |
| Checkpoint inhibitors | 8/220 (4) | 1/103 (1) | 7/125 (6) | .08 |
| Allogeneic HCT | 48/228 (21) | 26/103 (25) | 22/125 (18) | .16 |
| Clinical trials† | 38/228 (17) | 15/103 (15) | 23/125 (19) | .44 |
| FU post–auto-HCT relapse, mo | ||||
| Median | 39 | 63 | 35 | |
| Range | 1-72 | 5-72 | 1-72 | |
Data are n (%) unless otherwise indicated.
BEAM, carmustine, etoposide, cytarabine, and melphalan; ECOG, Eastern Cooperative Oncology Group; DHL, double-hit lymphoma; GCB, germinal center B-cell subtype; PS, performance status; THL, triple-hit lymphoma.
Patients with very early relapse after first-line therapy, those who achieved less than CR with first-line therapy, or those who were refractory to first-line therapy.
Information regarding specific agents was available in 28 patients; of these, 21 patients received small-molecule–targeted therapies, 4 patients received drug-antibody conjugates, and 3 patients received other therapies (azacytadine, n = 2; AZD9150, n = 1).